Agensys, Inc. engages in generating, developing, and manufacturing therapeutic fully human monoclonal antibodies (MAbs) to treat cancer. The company develops a pipeline of naked and antibody-drug conjugated (ADC) therapeutic antibodies to treat cancer indications, including prostate, kidney, pancreas, ovary, bladder, lung, colon, breast, and skin. The company develops AGS-1C4D4 for the treatment of pancreatic cancer; and various ADCs, such as AGS-16M8F, ASG-5ME, and ASG-22ME for treatment of various solid tumors. Agensys, Inc. was formerly known as UroGenesys, Inc. and changed its name to Agensys, Inc. in June 2001. The company was founded in 1996 and is based in Santa Monica, California. As...
1800 Stewart Street
Santa Monica, CA 90404
Founded in 1996
Bellicum Pharmaceuticals, Inc. and Agensys, Inc. Announce License Agreement for Cancer Target PSCA in Cell and Gene Therapy
Dec 11 15
Bellicum Pharmaceuticals, Inc. and Astellas Pharma Inc. announced that Agensys, Inc. have entered into a global license agreement, granting Bellicum rights to develop and commercialize adoptive cell therapies, including CAR-T cells, for tumors expressing Prostate Stem Cell Antigen (PSCA) using PSCA technology, both in-licensed and developed at Agensys. PSCA is a cancer antigen expressed in many malignancies, including prostate, pancreatic, bladder, esophagus, and gastric cancers. Bellicum is developing BPX-601, a GoCAR-T™ product candidate targeting PSCA that has demonstrated robust anti-tumor activity in preclinical studies. GoCAR-T is a proprietary Bellicum technology in which an MC (MyD88/CD40) molecular switch is designed to enable pharmacologic control over the activation, proliferation and persistence of the GoCAR-T cells in a patient. Under the terms and conditions of the license agreement, Agensys will receive an upfront license fee, and is eligible for clinical and sales milestones, as well as single-digit royalties on the sales of any products developed pursuant to the license. Astellas or Agensys retains the option for commercialization of any product targeting PSCA based on Bellicum’s CAR-T cell technology (e.g., BPX-601) in Japan. If the option is exercised, Bellicum would receive an option fee from Astellas or Agensys, and the amount for certain clinical and sales milestones to be paid to Agensys would be reduced. Bellicum would also receive royalties from Astellas or Agensys based upon sales of such product in Japan.